A 30,000 Foot View of TDP43 Direct Targeting Strategies – A Thought Experiment

• Overview of TDP-43 pathology as the central disease hallmark in the majority of ALS patients
• Current therapeutic approaches targeting TDP-43 loss of nuclear function
• Strategies aimed at mitigating toxic gain of function, aggregation, and cytoplasmic mislocalization
• Key lessons from the field, remaining translational challenges, and future directions for TDP-43–targeted therapies

Speakers:

Joyce Lo

Associate Director

Biogen